UTI Treatment Market Research Report Information By Drug Class (Quinolones, Aminoglycosides, Β-Lactam, Azoles and Others), By Clinical Indications (Urethritis, Cystitis and Pyelonephritis), By End User (Hospitals and Self-Administered), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2030.
ID: MRFR/Pharma/2268-HCR | 80 Pages | Published By Rahul Gotadki on March 2023
1 Introduction
1.1 Definition
1.2 Scope of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure:
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porter’s Five Forces Model
4.1.1 Bargaining Power of Suppliers
4.1.2 Bargaining Power of Customer
4.1.3 Intensity of Competitor’s
4.1.4 Threat of New Entrants
5 Global UTI Drugs Market, by Drug Class
5.1 Introduction
5.1.1 Quinolones
5.1.2 Aminoglycosides
5.1.3 β-lactam
5.1.4 Azoles
5.1.5 Others
6 Global UTI Drugs Market, by Clinical Indications
6.1 Introduction
6.1.1 Urethritis
6.1.2 Cystitis
6.1.3 Pyelonephritis
6.1.4 Others
7 Global UTI Drugs Market, by End User
7.1 Introduction
7.1.1 Hospitals
7.1.32 Self-administered
8 Global UTI Drugs Market, by Country
8.1 Introduction
8.2 UAE
8.3 Egypt
8.4 Saudi Arabia
8.5 Kuwait
8.6 Qatar
8.7 Oman
9 Company Landscape
9.1 Introduction
9.1.1 Mergers Acquisitions
9.1.2 Collaborations
9.1.3 Release/New Product Launches
9.1.4 Other (Expansion, Updates, Partnership)
10 Company Profile
10.1 Bayer AG
10.1.1 Company Overview
10.1.2 Product/Business Segment Overview
10.1.3 Financials
10.1.4 Key Developments
10.1.5 SWOT Analysis
10.2 Novartis AG
10.2.1 Overview
10.2.2 Product/Business Segment Overview
10.2.3 Financials
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 Pfizer Inc.
10.3.1 Overview
10.3.2 Product/Business Segment Overview
10.3.3 Financials
10.3.4 Key Developments
10.3.5 SWOT Analysis
10.4 F. Hoffmann-La Roche Ltd
10.4.1 Overview
10.4.2 Product/Business Segment Overview
10.4.3 Financials
10.4.4 Key Developments
10.4.5 SWOT Analysis
10.5 AstraZeneca
10.5.1 Overview
10.5.2 Product/Business Segment Overview
10.5.3 Financials
10.5.4 Key Developments
10.5.5 SWOT Analysis
10.6 Cipla Inc.
10.6.1 Overview
10.6.2 Product/Business Segment Overview
10.6.3 Financials
10.6.4 Key Developments
10.6.5 SWOT Analysis
10.7 Dr. Reddy’s Laboratories Ltd
10.7.1 Overview
10.7.2 Product/Business Segment Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 Johnson & Johnson
10.8.1 Overview
10.8.2 Product/Business Segment Overview
10.8.3 Financials
10.8.4 Key Developments
10.8.5 SWOT Analysis
10.9 Others
11 Conclusion
11.1 Key Findings
11.1.1 From CEO’S Viewpoint
11.1.2 Unmet Needs of the Market
11.2 Key Companies to Watch
11.3 Prediction of UTI Treatment Industry
12 Appendix
